Remove Clinical Research Remove Life Science Remove RNA
article thumbnail

Donidalorsen Shows Sustained HAE Attack Reduction According to New Trial Data

XTalks

Carlsbad, California-based Ionis Pharmaceuticals announced it will be sharing promising new trial data for its RNA-targeted prophylactic treatment donidalorsen for hereditary angioedema (HAE) at the 2025 American Academy of Allergy, Asthma & Immunology (AAAAI)/World Allergy Organization (WAO) Joint Congress in San Diego, California.

Trials 59
article thumbnail

Uptick in Clinical Trial Complexity: How Can You Achieve Your Clinical Trial Objectives Faster?

XTalks

“It’s important to make sure that with this increase in clinical trial complexity, we don’t make our trials overly burdensome to sites or patients,” says Markham. Keeping Trials on Track The preparation and analysis of samples within tight clinical trial timelines are crucial.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Vutrisiran Reduces Heart Risks for ATTR-CM Patients in Alnylam’s HELIOS-B Trial

XTalks

Alnylam Pharmaceuticals announced promising results from its HELIOS-B Phase III clinical trial evaluating vutrisiran, an investigational RNA interference (RNAi) therapeutic for treating transthyretin amyloidosis with cardiomyopathy (ATTR-CM). As of March 2024, the FDA has approved six small interfering RNA (siRNA) therapies.

Trials 52
article thumbnail

Oligonucleotide Therapeutics and Delivery Conference

pharmaphorum

The two-day conference will bring you high-quality insights and industry connections on the latest clinical trial candidates and a platform for exchanging ideas for tackling the biggest challenge: DELIVERY. CHAIRS FOR 2022: •Ekkehard Leberer, Senior Life Sciences Consultant, Elbicon. EARLY-BIRD RATES: ?BOOK

RNA 52
article thumbnail

Yale-NBA Partnership Results in FDA Approval for COVID-19 SalivaDirect Test

XTalks

The study was funded by a clinical research agreement with the NBA and the players’ union – the National Basketball Players Association (NDG) – which together, contributed over $500,000 to fund the Yale study. This is significant because shortages of RNA extraction kits have been a recurrent issue since the beginning of the pandemic.

article thumbnail

Krystexxa Chronic Gout Medication Gets Expanded FDA Approval

XTalks

Register for this free webinar for expert insights and an engaging discussion surrounding the utilization of electronic health record (EHR) data in clinical research and what the future might hold. Live and On-Demand: Tuesday, August 23, 2022, at 12pm EDT (5pm BST/UK). Gout is a significant therapeutic area for Horizon.

article thumbnail

How Can You Manage the Complexity of Early Phase Clinical Development?

XTalks

In the past, the majority of drugs evaluated in the clinical pharmacology space were small molecules. Today, there’s been a shift towards more complex, large molecules or biologics like monoclonal antibodies, antibody-drug conjugates (ADCs) and advanced therapies like RNA-based treatments and cell and gene therapies.